MPN-577: Favorable Benefit-Risk Profile of Avapritinib in Indolent Systemic Mastocytosis Is Maintained After 3 Years of Therapy: Longer-Term Analysis of the PIONEER Study
Year: 2025
Type: conference-abstract
Authors: Hanneke Oude Elberink, Cem Akin, Mariana Castells, Jason Gotlib, Jens Panse, Deepti H. Radia, Frank Siebenhaar, Tsewang Tashi, Cristina Bulai Livideanu, Karin Hartmann, Sigurd Broesby-Olsen, Tracy I. George, Vito Sabato, Paul Van Daele, Sonia Cerquozzi, Ingunn Dybedal, Joseph Jurcic, Stéphane Barete, Andreas Reiter, Thanai Pongdee, Ruchi Desai, Philipe Schafhausen, Celalettin Ustun, Prithviraj Bose, Peter Vadas, Massimo Triggiani, Patrizia Bonadonna, Daniel J. DeAngelo, Lindsay Rein, Pankit Vachhani, Ilda Bidollari, Hui-Min Lin, Janet Hong, Benjamin Lampson, Ashley Doyle, Ivan Alvarez-Twose
Institutions: University Medical Center Groningen, University of Groningen, University of Michigan, Brigham and Women's Hospital, Harvard University, Stanford Cancer Institute, Stanford University, Universitätsklinikum Aachen, RWTH Aachen University, Guy's and St Thomas' NHS Foundation Trust, Humboldt-Universität zu Berlin, Fraunhofer Institute for Translational Medicine and Pharmacology, Charité – Universitätsmedizin Berlin, Huntsman Cancer Institute, Centre Hospitalier Universitaire de Toulouse, University of Basel, University Hospital of Basel, Odense University Hospital, University of Utah, ARUP Laboratories (United States), University of Antwerp, Antwerp University Hospital, Erasmus MC, University of Calgary, Oslo University Hospital, Columbia University Irving Medical Center, Sorbonne Université, Assistance Publique – Hôpitaux de Paris, Pitié-Salpêtrière Hospital, Heidelberg University, Mayo Clinic, Virginia Commonwealth University, Virginia Commonwealth University Medical Center, University Medical Center Hamburg-Eppendorf, Rush University Medical Center, Rush University, The University of Texas MD Anderson Cancer Center, St. Michael's Hospital, University of Toronto, University of Salerno, Azienda Ospedaliera Universitaria Integrata Verona, Dana-Farber Cancer Institute, Duke University, Duke Medical Center, University of Alabama at Birmingham, Blueprint Medicines (United States), Hospital Virgen del Valle
Language: English
Topic: Mast cells and histamine
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W4413781907